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Aim
To summarize evidence regarding the effectiveness of
Methotrexate (MTX) in the treatment of childhood
autoimmune chronic uveitis.
Methods
A systematic search of articles published between Janu-
ary 1990 and February 2011 was conducted using fol-
lowing electronic databases: EMBASE, Ovid MEDLINE,
EBM Reviewers–ACP Journal Club, all Cochrane library,
and EBM Reviews–Database of Abstracts of Reviews of
effects. Reference list and citations of those identified
were also screened to find out relevant papers. Studies
investigating the efficacy of MTX, as a single immuno-
suppressant medication in the treatment of chronic
autoimmune uveitis, refractory to therapy with topic
treatment and/or systemic treatment, in children (≤16
yrs) were eligible for inclusion. Primary outcome mea-
sure was the improvement of intraocular inflammation
as Tyndall, as defined by the SUN working group cri-
teria. When reported and available, tapering and/or
stopping systemic steroid administration, improvement
in visual acuity post MTX treatment, discontinuation of
MTX, time for remission, time on remission, and safety
of treatment were also considered as additional second-
ary additional outcomes. We determined a combined
estimate of the proportion of children in the eligible stu-
dies responding to MTX. The effect measure for each
study was therefore the proportion of people classified
as responders.
Results
Fifty-two potential eligible articles were selected for
detailed review of the 246 found by the initial computer-
ized search and then scrutinized applying the selection
criteria. A total of 9 articles were strictly eligible and
remained in the analysis. All of the included studies
were retrospective chart reviews. Number of children in
these studies ranged from 3 to 25 and the dose of MTX
varied from 7.5 mg/mq
2 to 30 mg/mq
2.A l t o g e t h e r ,7 5
children out 135 included responded to the treatment.
The pooled analysis suggested that MTX has favourable
effect in the improvement of intraocular inflammation:
0.73 (95% CI: 0.66-0.81).
Conclusion
The available evidence supports the use of MTX in the
treatment of childhood chronic uveitis: patients on
MTX can expect a 73% probability of improvement in
intraocular inflammation; however randomised con-
trolled trials on MTX are necessary before a firm con-
clusion can be drawn.
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